Evidence map›Paper›PMID 41953194›Full record

ArticleFrontiers in pharmacology2026

Assessing the limitations of paraformaldehyde fixation for accurate cell surface receptor measurement.

Emma Bernard, Amandine Wahart, Nicolas Pataluch, Céline Galés, Véronique Pons

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emma BernardINSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de Toulouse, Toulouse, France.
Amandine Wahart *INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de Toulouse, Toulouse, France.
Nicolas Pataluch *INSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de Toulouse, Toulouse, France.
Céline GalésINSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de Toulouse, Toulouse, France.
Véronique PonsINSERM, UMR 1297, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de Toulouse, Toulouse, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Quantifying cell surface receptors, distinct from the total cellular receptor pool, which includes both intracellular and membrane-bound compartments, is imperative in cell biology and pharmacology. Cell surface receptors are pivotal for initiating signaling cascades in response to extracellular stimuli, making their accurate quantification critical for understanding initial cellular responses and signal transduction mechanisms. Methods: Whole-cell Enzyme-Linked Immunosorbent Assays (ELISA) are commonly used to assess receptor expression in both permeabilized and non-permeabilized cells. Using angiotensin II type 1 receptor (AT1-R) and sorting nexin 12 (SNX12) as models for cell surface and intracellular proteins, respectively, we evaluated the impact of paraformaldehyde (PFA) fixation on protein quantification. Results: We found that a fixation step with 4% paraformaldehyde (PFA), widely employed across biological protocols, significantly permeabilizes cellular membranes. This results in the unintended detection of intracellular proteins in non-permeabilized cells, thereby leading to inaccurate measurements of plasma membrane receptor expression. Reducing the PFA concentration to 1% substantially improved the accuracy of cell surface receptor quantification by limiting membrane permeabilization while maintaining total receptor content. This adjustment was particularly important when assessing the surface expression of certain GPCR mutants that are retained intracellularly. However, the effect was protein-dependent, as 1% PFA caused inadequate protein immobilization and partial loss of some cytosolic proteins. Discussion: These findings underscore the necessity for tailored fixation protocols, depending on the protein of interest, in order to preserve cell surface integrity and ensure reliable quantification of proteins in diverse biological studies.

Indexed as

cell surface quantificationELISAG protein-coupled receptorparaformaldehyde fixationpermeabilization

Identifiers

PMID41953194
PMCPMC13055513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.